SCHEMBL11943816

SCHEMBL11943816

CCOCCOc1c(N2CCN(Cc3ccccc3)CC2)cnn(-c2cccc(Cl)c2)c1=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.51
▸ MAPT P10636 5/20 0.44
▸ ALDH1A1 P00352 4/20 0.44
▸ SMN1; SMN2 Q16637 2/20 0.44
▸ DCTPP1 Q9H773 1/20 0.43
▸ RXFP1 Q9HBX9 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ PPARG P37231 1/20 0.43
▸ NCOA2 Q15596 1/20 0.43
▸ NCOA1 Q15788 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NCOA3 Q9Y6Q9 1/20 0.43
▸ NPBWR1 P48145 2/20 0.43
▸ MCHR1 Q99705 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ THRB P10828 1/20 0.43
▸ DRD2 P14416 1/20 0.42
▸ DRD4 P21917 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943549 0.91 POLB (0.45) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11943833 0.89 SMO (0.48) LMNAMAPTALDH1A1SMN1; SMN2POLB
SCHEMBL17058031 0.88 MAPT (0.41) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11943951 0.88 MAPT (0.53) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL17058040 0.87 NPSR1 (0.41) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11943992 0.86 POLB (0.58) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11944002 0.86 MAPT (0.51) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11943548 0.85 NPBWR1 (0.45) MAPTALDH1A1SMN1; SMN2DCTPP1RXFP1
SCHEMBL17058298 0.85 POLB (0.40) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1
SCHEMBL11945071 0.85 ALDH1A1 (0.54) LMNAMAPTALDH1A1SMN1; SMN2DCTPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA LMNA 929/4885MAPT 2295/4885ALDH1A1 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback